Our lead compound as a host-modulator, CMC2.24, orally administered to two rat models of disease [the locally-induced (microbial endotoxin/LPS) disease, periodontitis, and the systemic disease, diabetes], resulted in a marked reduction of inflammatory cytokines and MMPs in the gingival tissues, decreased bone loss, and decreased activation of p65 Nuclear factor-kappa B (NFκB) and p38 Mitogen-activated protein kinase (MAPK) (28). This evidence concerns the gene NFKB1 and diabetes mellitus.